bicalutamide has been researched along with 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Ates-Alagoz, Z; Gediya, LK; Godbole, AM; Kwegyir-Afful, AK; Martin, MS; Njar, VC; Purushottamachar, P; Ramalingam, S; Vasaitis, TS | 1 |
| Brodie, AM; Njar, VC | 1 |
| Brodie, AM; Goloubeva, O; Njar, VC; Sabnis, G; Schayowitz, A | 1 |
| Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K | 1 |
5 other study(ies) available for bicalutamide and 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene
| Article | Year |
|---|---|
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Topics: Androstadienes; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Transcriptional Activation | 2013 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discovery; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tissue Distribution | 2015 |
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Anilides; Animals; Benzimidazoles; Castration; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Everolimus; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor Cross-Talk; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays | 2010 |
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques | 2017 |